GLP-1RA Alzheimer’s hopes dashed after Novo Nordisk’s semaglutide miss
Novo Nordisk’s Rybelsus (oral semaglutide) has failed to demonstrate efficacy in a late-stage trial in Alzheimer’s disease, denting hopes of…
24 Nov 2025
Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club
Eli Lilly’s market capitalisation hit the $1tn mark in the past week, becoming the first healthcare company in the world to join the exclusive club dominated by technology companies. Buoyed…
24 Nov 2025
Navigating the FDA’s import operations for pharmaceuticals and biologics
In August 2025, the US Food and Drug Administration’s (FDA) launched the nationalised entry review (NER) programme focused on centralising import reviews and moved away from the previous divisional structure.…
24 Nov 2025
Investors bet on newer technology and indications for CGTs
As confidence grows for innovative in vivo strategies, some investors are saying they could be the future of the cell and gene therapy (CGT) sector. In recent months, several high-profile…
24 Nov 2025
AstraZeneca to expand biomanufacturing in Maryland, US
AstraZeneca has announced a $2bn investment plan to expand its biomanufacturing presence in the US state of Maryland, aiming to support 2,600 jobs at its Frederick and Gaithersburg sites. The…
24 Nov 2025
Vaximm and BCME link on oral cancer immunotherapy platform
OSR Company Vaximm has signed a non-binding term sheet with Swiss-based life sciences investor BCM Europe (BCME) for a potential exclusive worldwide licence for Vaximm’s oral cancer immunotherapy platform, VXM01.…
21 Nov 2025
“Reckless and harmful”: experts weigh in on CDC’s autism-vaccine link stance
The Centers for Disease Control and Prevention (CDC) has updated its website to state that there could be a link between autism and vaccines. The decision to now publicly state…